Development of an in vitro assay as correlate of passive immune protection against botulinum neurotoxin to minimize use of whole animal testing

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W81XWH-11-C-0085
Agency Tracking Number: C2-0367
Amount: $999,988.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD11-109
Solicitation Number: 2011.1
Solicitation Year: 2011
Award Year: 2012
Award Start Date (Proposal Award Date): 2012-05-24
Award End Date (Contract End Date): 2014-09-23
Small Business Information
5754 Pacific Center Blvd Suite 204, San Diego, CA, -
DUNS: 129852864
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Eric Ervin
 Vice President of R&D
 (801) 582-0146
Business Contact
 Tracey Wrightson
Title: Director of Operations
Phone: (858) 412-1800
Research Institution
This Small Business Innovation Research project will develop a non-animal based in vitro assay for determining the efficacy of Botulinum (BoNT) neutralizing therapeutics. New technologies are currently needed in order to facilitate the development and approval of BoNT vaccines and therapies and reduce the number of vertebrate animals used in medical testing. In Phase 1 of this project, the feasibility of the proposed system was demonstrated. During Phase 2, a complete working prototype will now be built, tested and validated against the standard mouse lethality neutralization (MLN) assay. Electronic BioSciences"proposed system will be capable of monitoring the complete neutralizing mechanism of therapies to all seven BoNT serotypes, making rapid, non-animal based neutralization efficacy testing possible.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government